adalimumab
abbvie
[]
 bdmard: no order of preference proposed for peripheral arthritis rcts are mostly not of h2h data h2h rcts of il17i vs ada: similar efficacy on the joints (acr20, acr50 responses) #eular2023
@bu_bmc_rheum | @rheum_covid @spartan_updates @official_asas | @UWRheum @UWEpidemiology 2020 | @OHSUIMres 2017 | @UTMBhealth 2014 | @UTAustin 2010